Reproductive milestones across the lifespan and cardiovascular disease risk in women

References

• World Heart Federation. What is cardiovascular disease? [cited 2023 June 24]. Available from: https://world-heart-federation.org/what-is-cvd/
   Google Scholar
• World Heart Federation. Women & CVD. [cited 2023 June 24]. Available from: https://world-heart-federation.org/what-we-do/women-cvd/
   Google Scholar
• Vogel B, Acevedo M, Appelman Y, et al. The lancet women and cardiovascular disease commission: reducing the global burden by 2030. Lancet. 2021;397(10292):2385–2438. doi: 10.1016/S0140-6736(21)00684-X.
   PubMed Web of Science ®Google Scholar
• Wenger NK, Lloyd-Jones DM, Elkind MSV, et al. Call to action for cardiovascular disease in women: epidemiology, awareness, access, and delivery of equitable health care: a presidential advisory from the American Heart Association. Circulation. 2022;145(23):e1059–e1071. doi: 10.1161/CIR.0000000000001071.
   PubMed Web of Science ®Google Scholar
• Mosca L, Linfante AH, Benjamin EJ, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation. 2005;111(4):499–510. doi: 10.1161/01.CIR.0000154568.43333.82.
   PubMed Web of Science ®Google Scholar
• Leifheit-Limson EC, D’Onofrio G, Daneshvar M, et al. Sex differences in cardiac risk factors, perceived risk, and health care provider ­discussion of risk and risk modification among young patients with acute myocardial infarction: the VIRGO study. J Am Coll Cardiol. 2015;66(18):1949–1957. doi: 10.1016/j.jacc.2015.08.859.
   PubMed Web of Science ®Google Scholar
• Cushman M, Shay CM, Howard VJ, et al. Ten-Year differences in women’s awareness related to coronary heart disease: results of the 2019 American Heart Association national survey: a special report from the American Heart Association. Circulation. 2021;143(7):e239–e248. doi: 10.1161/CIR.0000000000000907.
   PubMed Web of Science ®Google Scholar
• Mehta LS, Beckie TM, DeVon HA, et al. Acute myocardial infarction in women. A scientific statement from the American Heart Association. Circulation. 2016;133(9):916–947. doi: 10.1161/CIR.0000000000000351.
   PubMed Web of Science ®Google Scholar
• Stuenkel CA. Do we have new preventive strategies for optimizing cardiovascular health in women? Climacteric. 2019;22(2):133–139. doi: 10.1080/13697137.2018.1561665.
   PubMed Web of Science ®Google Scholar
• Aggarwal NR, Patel HN, Mehta LS, et al. Sex differences in ischemic heart disease: advances, obstacles, and next steps. Circ Cardiovasc Qual Outcomes. 2018;11(2):e004437. doi: 10.1161/CIRCOUTCOMES.117.004437.
   PubMed Web of Science ®Google Scholar
• Agarwala A, Michos ED, Samad Z, et al. The use of sex-specific factors in the assessment of women’s cardiovascular risk. Circulation. 2020;141(7):592–599. doi: 10.1161/CIRCULATIONAHA.119.043429.
   PubMed Web of Science ®Google Scholar
• Elder P, Sharma G, Gulati M, et al. Identification of female-specific risk enhancers throughout the lifespan of women to improve cardiovascular disease prevention. Am J Prev Cardiol. 2020;2:100028. doi: 10.1016/j.ajpc.2020.100028.
   PubMedGoogle Scholar
• Maas AHEM, Rosano G, Cifkova R, et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur Heart J. 2021;42(10):967–984. Erratum in: Eur Heart J. 2022 Jul 1;43(25):2372. doi: 10.1093/eurheartj/ehaa1044.
   PubMed Web of Science ®Google Scholar
• O’Kelly AC, Michos ED, Shufelt CL, et al. Pregnancy and reproductive risk factors for cardiovascular disease in women. Circ Res. 2022;130(4):652–672. doi: 10.1161/CIRCRESAHA.121.319895.
   PubMed Web of Science ®Google Scholar
• Kim C, Catov J, Schreiner PJ, et al. Women’s reproductive milestones and cardiovascular disease risk: a review of reports and opportunities from the CARDIA study. J Am Heart Assoc. 2023;12(5):e028132. doi: 10.1161/JAHA.122.028132.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Chedraui P, Lambrinoudaki I, et al. Menopause: a cardiometabolic transition. Lancet Diabetes Endocrinol. 2022;10(6):442–456. doi: 10.1016/S2213-8587(22)00076-6.
   PubMed Web of Science ®Google Scholar
• Roeters van Lennep JE, Tokgözoğlu LS, Badimon L, et al. Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society. Eur Heart J. 2023;ehad472. doi: 10.1093/eurheartj/ehad472.
   PubMedGoogle Scholar
• Xiao B, Velez Edwards DR, Lucas A, et al. Inference of causal relationships between genetic risk factors for cardiometabolic phenotypes and female-specific health conditions. J Am Heart Assoc. 2023;12(5):e026561. doi: 10.1161/JAHA.121.026561.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–e1143. Erratum in: Circulation. 2019 Jun 18;139(25): e1182-e1186. doi: 10.1161/CIR.0000000000000625.
   PubMed Web of Science ®Google Scholar
• ACOG Committee Opinion. No 651: menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Obstet Gynecol. 2015;126(6):e143–e146. doi: 10.1097/AOG.0000000000001215.
   PubMedGoogle Scholar
• Ley SH, Li Y, Tobias DK, et al. Duration of reproductive life span, age at menarche, and age at menopause are associated with risk of cardiovascular disease in women. J Am Heart Assoc. 2017;6(11):e006713. doi: 10.1161/JAHA.117.006713.
   PubMed Web of Science ®Google Scholar
• Okoth K, Chandan JS, Marshall T, et al. Association between the reproductive health of young women and cardiovascular disease in later life: umbrella review. BMJ. 2020;371:m3502. Erratum in: BMJ. 2020 Oct 14;371:m3963. doi: 10.1136/bmj.m3502.
   PubMed Web of Science ®Google Scholar
• Wang YX, Arvizu M, Rich-Edwards JW, et al. Menstrual cycle regularity and length across the reproductive lifespan and risk of premature mortality: prospective cohort study. BMJ. 2020;371:m3464. doi: 10.1136/bmj.m3464.
   PubMedGoogle Scholar
• Osibogun O, Ogunmoroti O, Michos ED. Polycystic ovary syndrome and cardiometabolic risk: opportunities for cardiovascular disease prevention. Trends Cardiovasc Med. 2020;30(7):399–404. doi: 10.1016/j.tcm.2019.08.010.
   PubMed Web of Science ®Google Scholar
• Zhang J, Xu JH, Qu QQ, et al. Risk of cardiovascular and cerebrovascular events in polycystic ovarian syndrome women: a meta-analysis of cohort studies. Front Cardiovasc Med. 2020;7:552421. doi: 10.3389/fcvm.2020.552421.
   PubMed Web of Science ®Google Scholar
• Cardiovascular Risk Across the Lifespan for Polycystic Ovary Syndrome Workshop, October 22, 2021. [cited 2023 Jul 26] https://www.nhlbi.nih.gov/events/2021/cardiovascular-risk-across-lifespan-polycystic-ovary-syndrome-workshop
   Google Scholar
• Teede HJ, Thien Tay C, Laven JJE, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023 Sep 18;108(10):2447–2469. doi: 10.1210/clinem/dgad463.
   PubMedGoogle Scholar
• Shufelt CL, Torbati T, Dutra E. Hypothalamic amenorrhea and the long-term health consequences. Semin Reprod Med. 2017;35(3):256–262. doi: 10.1055/s-0037-1603581.
   PubMed Web of Science ®Google Scholar
• Kuehn BM. Rising heart risks for young women linked to low estrogen. Circulation. 2019;139(4):549–550. doi: 10.1161/CIRCULATIONAHA.118.038754.
   PubMed Web of Science ®Google Scholar
• Kaplan JR, Manuck SB, Anthony MS, et al. Premenopausal social status and hormone exposure predict postmenopausal atherosclerosis in female monkeys. Obstet Gynecol. 2002;99(3):381–388.
   PubMed Web of Science ®Google Scholar
• Bairey Merz CN, Berga S, Cook-Weins G, et al. OR19-6 functional hypothalamic amenorrhea and preclinical cardiovascular disease. J Endocr Soc. 2022;6(Suppl_1):A249–A249. doi: 10.1210/jendso/bvac150.512.
   Google Scholar
• Johansson T, Fowler P, Ek WE, et al. Oral contraceptives, hormone replacement therapy, and stroke risk. Stroke. 2022;53(10):3107–3115. doi: 10.1161/STROKEAHA.121.038659.
   PubMed Web of Science ®Google Scholar
• US Medical Eligibility Criteria for Contraceptive Use, 2016 (US MEC). Source: Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion. 2023 Mar 27. [cited 2023 Sept 6]. https://www.cdc.gov/reproductivehealth/contraception/mmwr/mec/appendixD.html#mec_personal
   Google Scholar
• Fabunmi OA, Dludla PV, Nkambule BB. Investigating cardiovascular risk in premenopausal women on oral contraceptives: systematic review with meta-analysis. Front Cardiovasc Med. 2023;10:1127104. doi: 10.3389/fcvm.2023.1127104.
   PubMed Web of Science ®Google Scholar
• UpToDate. Combined estrogen-progestin contraception: side effects and health concerns. Last updated 2023 Mar 27. [cited 2023 Sept 6]. https://www.uptodate.com/contents/combined-estrogen-progestin-contraception-side-effects-and-health-concerns/print?search=risks%20and%20benefit%20of%20progestogens%20in%20oral%20contraceptives&source=search_result&selectedTitle=2∼150&usage_type=default&display_rank.=2
   Google Scholar
• Barsky L, Shufelt C, Lauzon M, et al. Prior oral contraceptive use and longer-term mortality outcomes in women with suspected ischemic heart disease. J Womens Health (Larchmt). 2021;30(3):377–384. doi: 10.1089/jwh.2020.8743.
   PubMed Web of Science ®Google Scholar
• Farland LV, Wang YX, Gaskins AJ, et al. Infertility and risk of cardiovascular disease: a prospective cohort study. J Am Heart Assoc. 2023;12(5):e027755. doi: 10.1161/JAHA.122.027755.
   PubMed Web of Science ®Google Scholar
• Lau ES, Wang D, Roberts M, et al. Infertility and risk of heart failure in the women’s health initiative. J Am Coll Cardiol. 2022;79(16):1594–1603. doi: 10.1016/j.jacc.2022.02.020.
   PubMed Web of Science ®Google Scholar
• Zahid S, Hashem A, Minhas AS, et al. Cardiovascular complications during delivery admissions associated with assisted reproductive technology (from a national inpatient sample analysis 2008 to 2019). Am J Cardiol. 2023;186:126–134. doi: 10.1016/j.amjcard.2022.08.037.
   PubMed Web of Science ®Google Scholar
• Brown HL, Warner JJ, Gianos E, et al. Promoting risk identification and reduction of cardiovascular disease in women through collaboration with obstetricians and gynecologists: a presidential advisory from the American Heart Association and the American College of Obstetricians and Gynecologists. Circulation. 2018;137(24):e843–e852. doi: 10.1161/CIR.0000000000000582.
   PubMed Web of Science ®Google Scholar
• Hauspurg A, Ying W, Hubel CA, et al. Adverse pregnancy outcomes and future maternal cardiovascular disease. Clin Cardiol. 2018;41(2):239–246. doi: 10.1002/clc.22887.
   PubMed Web of Science ®Google Scholar
• Stuart JJ, Tanz LJ, Rimm EB, et al. Cardiovascular risk factors mediate the long-term maternal risk associated with hypertensive disorders of pregnancy. J Am Coll Cardiol. 2022;79(19):1901–1913. doi: 10.1016/j.jacc.2022.03.335.
   PubMed Web of Science ®Google Scholar
• Rayes B, Ardissino M, Slob EAW, et al. Association of hypertensive disorders of pregnancy with future cardiovascular disease. JAMA Netw Open. 2023;6(2):e230034. doi: 10.1001/jamanetworkopen.2023.0034.
   PubMed Web of Science ®Google Scholar
• Khan SS, Brewer LC, Canobbio MM, et al. Optimizing prepregnancy cardiovascular health to improve outcomes in pregnant and postpartum individuals and offspring: a scientific statement from the American Heart Association. Circulation. 2023;147(7):e76–e91. doi: 10.1161/CIR.0000000000001124.
   PubMed Web of Science ®Google Scholar
• Yang L, Huang C, Zhao M, et al. Maternal hypertensive disorders during pregnancy and the risk of offspring diabetes mellitus in childhood, adolescence, and early adulthood: a nationwide population-based cohort study. BMC Med. 2023;21(1):59. doi: 10.1186/s12916-023-02762-5.
   PubMed Web of Science ®Google Scholar
• Mehta LS, Warnes CA, Bradley E, et al. Cardiovascular considerations in caring for pregnant patients: a scientific statement from the American Heart Association. Circulation. 2020;141(23):e884–e903. doi: 10.1161/CIR.0000000000000772. Erratum in: Circulation. 2020 Jun 9;141(23): e904. Erratum in: Circulation. 2021 Mar 23;143(12): e792–e793.
   PubMed Web of Science ®Google Scholar
• Parikh NI, Gonzalez JM, Anderson CAM, et al. Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities for cardiovascular disease prevention in women: a scientific statement from the American Heart Association. Circulation. 2021;143(18):e902–e916. doi: 10.1161/CIR.0000000000000961.
   PubMed Web of Science ®Google Scholar
• Jowell AR, Sarma AA, Gulati M, et al. Interventions to mitigate risk of cardiovascular disease after adverse pregnancy outcomes: a review. JAMA Cardiol. 2022;7(3):346–355. doi: 10.1001/jamacardio.2021.4391. Erratum in: JAMA Cardiol. 2023 Jun 14.
   PubMed Web of Science ®Google Scholar
• Graves CR, Woldemichael RM, Davis SF. Cardio-obstetrics: moving beyond programming to action. J Am Heart Assoc. 2023;12(5):e028141. doi: 10.1161/JAHA.122.028141.
   PubMed Web of Science ®Google Scholar
• Mehta LS, Watson KE, Barac A, et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation. 2018;137(8):e30–e66. doi: 10.1161/CIR.0000000000000556. Erratum in: Circulation. 2019 Aug 27;140(9): e543.
   PubMed Web of Science ®Google Scholar
• Kc M, Fan J, Hyslop T, et al. Relative burden of cancer and noncancer mortality among long-term survivors of breast, prostate, and colorectal cancer in the US. JAMA Netw Open. 2023;6(7):e2323115. doi: 10.1001/jamanetworkopen.2023.23115.
   PubMed Web of Science ®Google Scholar
• Khosrow-Khavar F, Filion KB, Bouganim N, et al. Aromatase inhibitors and the risk of cardiovascular outcomes in women with breast cancer: a population-based cohort study. Circulation. 2020;141(7):549–559. doi: 10.1161/CIRCULATIONAHA.119.044750.
   PubMed Web of Science ®Google Scholar
• Barish R, Lynce F, Unger K, et al. Management of cardiovascular disease in women with breast cancer. Circulation. 2019;139(8):1110–1120. doi: 10.1161/CIRCULATIONAHA.118.039371.
   PubMed Web of Science ®Google Scholar
• Carlson LE, Watt GP, Tonorezos ES, et al. Coronary artery disease in young women after radiation therapy for breast cancer: the WECARE study. JACC CardioOncol. 2021;3(3):381–392. doi: 10.1016/j.jaccao.2021.07.008.
   PubMedGoogle Scholar
• Jacobs JEJ, L’Hoyes W, Lauwens L, et al. Mortality and major ­adverse cardiac events in patients with breast cancer receiving ­radiotherapy: the first decade. J Am Heart Assoc. 2023;12(8):e027855. doi: 10.1161/JAHA.122.027855.
   PubMed Web of Science ®Google Scholar
• Okwuosa TM, Morgans A, Rhee JW, et al. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association. Circ Genom Precis Med. 2021;14(3):e000082. doi: 10.1161/HCG.0000000000000082.
   PubMed Web of Science ®Google Scholar
• Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975–4011. doi: 10.1210/jc.2015-2236.
   PubMed Web of Science ®Google Scholar
• El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American heart association. Circulation. 2020;142(25):e506–e532. doi: 10.1161/CIR.0000000000000912.
   PubMed Web of Science ®Google Scholar
• Tepper PG, Brooks MM, Randolph JFJr, et al. Characterizing the trajectories of vasomotor symptoms across the menopausal transition. Menopause. 2016;23(10):1067–1074. doi: 10.1097/GME.0000000000000676.
   PubMed Web of Science ®Google Scholar
• Choi HR, Chang Y, Kim Y, et al. Ideal cardiovascular health metrics and risk of incident early-onset vasomotor symptoms among premenopausal women. J Clin Endocrinol Metab. 2022;107(9):2666–2673. doi: 10.1210/clinem/dgac327.
   PubMed Web of Science ®Google Scholar
• Thurston RC. Vasomotor symptoms: natural history, physiology, and links with cardiovascular health. Climacteric. 2018;21(2):96–100. doi: 10.1080/13697137.2018.1430131.
   PubMed Web of Science ®Google Scholar
• Zhu D, Chung HF, Dobson AJ, et al. Vasomotor menopausal symptoms and risk of cardiovascular disease: a pooled analysis of six prospective studies. Am J Obstet Gynecol. 2020;223(6):898.e1–898.e16. doi: 10.1016/j.ajog.2020.06.039.
   PubMed Web of Science ®Google Scholar
• Thurston RC, Aslanidou Vlachos HE, Derby CA, et al. Menopausal vasomotor symptoms and risk of incident cardiovascular disease events in SWAN. J Am Heart Assoc. 2021;10(3):e017416. doi: 10.1161/JAHA.120.017416.
   PubMed Web of Science ®Google Scholar
• Cortés YI, Conant R, Catov JM, et al. Impact of nulliparity, hypertensive disorders of pregnancy, and gestational diabetes on vasomotor symptoms in midlife women. Menopause. 2020;27(12):1363–1370. doi: 10.1097/GME.0000000000001628.
   PubMed Web of Science ®Google Scholar
• Faubion SS, King A, Kattah AG, et al. Hypertensive disorders of pregnancy and menopausal symptoms: a cross-sectional study from the data registry on experiences of aging, menopause, and sexuality. Menopause. 2020;28(1):25–31. doi: 10.1097/GME.0000000000001638.
   PubMed Web of Science ®Google Scholar
• Zhu D, Chung HF, Dobson AJ, et al. Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. Lancet Public Health. 2019;4(11):e553–e564. doi: 10.1016/S2468-2667(19)30155-0.
   PubMed Web of Science ®Google Scholar
• Mishra SR, Chung HF, Waller M, et al. Duration of estrogen exposure during reproductive years, age at menarche and age at menopause, and risk of cardiovascular disease events, all-cause and cardiovascular mortality: a systematic review and meta-analysis. BJOG. 2021;128(5):809–821. doi: 10.1111/1471-0528.16524.
   PubMed Web of Science ®Google Scholar
• Honigberg MC, Zekavat SM, Aragam K, et al. Association of premature natural and surgical menopause with incident cardiovascular disease. JAMA. 2019;322(24):2411–2421. doi: 10.1001/jama.2019.19191.
   PubMed Web of Science ®Google Scholar
• Hall PS, Nah G, Howard BV, et al. Reproductive factors and incidence of heart failure hospitalization in the women’s health initiative. J Am Coll Cardiol. 2017;69(20):2517–2526. doi: 10.1016/j.jacc.2017.03.557.
   PubMed Web of Science ®Google Scholar
• Appiah D, Winters SJ, Hornung CA. Bilateral oophorectomy and the risk of incident diabetes in postmenopausal women. Diabetes Care. 2014;37(3):725–733. doi: 10.2337/dc13-1986.
   PubMed Web of Science ®Google Scholar
• Manson JE, Woodruff TK. Reproductive health as a marker of subsequent cardiovascular disease: the role of estrogen. JAMA Cardiol. 2016;1(7):776–777. doi: 10.1001/jamacardio.2016.2662.
   PubMed Web of Science ®Google Scholar
• Laven JSE. Genetics of menopause and primary ovarian insufficiency: time for a paradigm shift? Semin Reprod Med. 2020;38(4-05):256–262. doi: 10.1055/s-0040-1721796.
   PubMed Web of Science ®Google Scholar
• Zhu D, Chung HF, Pandeya N, et al. Premenopausal cardiovascular disease and age at natural menopause: a pooled analysis of over 170,000 women. Eur J Epidemiol. 2019;34(3):235–246. Mardoi: 10.1007/s10654-019-00490-w.
   PubMed Web of Science ®Google Scholar
• Stuenkel CA. Menopausal hormone therapy and the role of estrogen. Clin Obstet Gynecol. 2021;64(4):757–771. doi: 10.1097/GRF.0000000000000648.
   PubMed Web of Science ®Google Scholar
• Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1995;273(3):199–208. Erratum in: JAMA 1995 Dec 6;274(21):1676.
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605–613. doi: 10.1001/jama.280.7.605.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465–1477. doi: 10.1001/jama.297.13.1465. Erratum in: JAMA. 2008 Mar 26;299(12):1426.
   PubMed Web of Science ®Google Scholar
• Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended post stopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013; Oct 2310(13):1353–1368. doi: 10.1001/jama.2013.278040.
   PubMed Web of Science ®Google Scholar
• Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women’s health initiative randomized trials. JAMA. 2017;318(10):927–938. doi: 10.1001/jama.2017.11217.
   PubMed Web of Science ®Google Scholar
• Manson JE, Aragaki AK, Bassuk SS, et al. Menopausal estrogen-alone therapy and health outcomes in women with and without bilateral oophorectomy: a randomized trial. Ann Intern Med. 2019;171(6):406–414. doi: 10.7326/M19-0274.
   PubMed Web of Science ®Google Scholar
• Zhang GQ, Chen JL, Luo Y, et al. Menopausal hormone therapy and women’s health: an umbrella review. PLoS Med. 2021;18(8):e1003731. doi: 10.1371/journal.pmed.1003731.
   PubMed Web of Science ®Google Scholar
• Baber RJ, Panay N, Fenton A, IMS Writing Group. 2016 IMS (International Menopause Society) recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–150. doi: 10.3109/13697137.2015.1129166.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE): guideline on menopause—diagnosis and management. [Published 2015 Nov 12; updated 2019 Dec 5]. Available from: www.nice.org.uk.guidance/ng23.
   Google Scholar
• ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstet Gynecol. 2014;123(1):202–216. doi: 10.1097/01.AOG.0000441353.20693.78.Erratum in: obstet Gynecol. 2016 Jan;127(1):166. Erratum in: Obstet Gynecol. 2018 Mar;131(3):604.
   PubMed Web of Science ®Google Scholar
• “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. doi: 10.1097/GME.0000000000002028.
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–845. doi: 10.1161/CIRCULATIONAHA.106.642280.
   PubMed Web of Science ®Google Scholar
• Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol. 2010;30(2):340–345. doi: 10.1161/ATVBAHA.109.196022.
   PubMed Web of Science ®Google Scholar
• Sweetland S, Beral V, Balkwill A, et al. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost. 2012;10(11):2277–2286. doi: 10.1111/j.1538-7836.2012.04919.x.
   PubMed Web of Science ®Google Scholar
• Clarkson TB, Melendez GC, Appt SE. Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. Menopause. 2013;20(3):342–353. doi: 10.1097/GME.0b013e3182843aad.
   PubMed Web of Science ®Google Scholar
• Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345(oct09 2):e6409–e6409. doi: 10.1136/bmj.e6409.
   PubMed Web of Science ®Google Scholar
• Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women. Ann Intern Med. 2014;161(4):249–260. doi: 10.7326/M14-0353.
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221–1231. doi: 10.1056/NEJMoa1505241.
   PubMed Web of Science ®Google Scholar
• Stuenkel CA. Managing menopausal vasomotor symptoms in older women. Maturitas. 2021;143:36–40. doi: 10.1016/j.maturitas.2020.08.005.
   PubMed Web of Science ®Google Scholar
• Committee Opinion No. 698: hormone therapy in primary ovarian insufficiency. American college of obstetricians and gynecologists. Obstet Gynecol. 2017;129(5):e134–e141. doi: 10.1097/AOG.0000000000002044.
   PubMed Web of Science ®Google Scholar
• Neves-e-Castro M, Birkhauser M, Samsioe G, et al. EMAS position statement: the ten-point guide to the integral management of menopausal health. Maturitas. 2015;81(1):88–92. doi: 10.1016/j.maturitas.2015.02.003.
   PubMed Web of Science ®Google Scholar
• Webber L, Davies M, Anderson R, et al. ESHRE guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926–937. Maydoi: 10.1093/humrep/dew027.
   PubMed Web of Science ®Google Scholar
• Panay N, Anderson R, Nappi R, et al. Premature ovarian insufficiency: an International Menopause Society white paper. Climacteric. 2020;23(5):426–446. doi: 10.1080/13697137.2020.1804547.
   PubMed Web of Science ®Google Scholar
• Stuenkel CA, Gompel A, Davis SR, et al. Approach to the patient with new-onset secondary amenorrhea: is this primary ovarian insufficiency? J Clin Endocrinol Metab. 2022;107(3):825–835. doi: 10.1210/clinem/dgab766.
   PubMed Web of Science ®Google Scholar
• Stuenkel CA, Gompel A. Primary ovarian insufficiency. N Engl J Med. 2023;388(2):154–163. doi: 10.1056/NEJMcp2116488.
   PubMed Web of Science ®Google Scholar
• Liu J, Jin X, Liu W, et al. The risk of long-term cardiometabolic disease in women with premature or early menopause: a systematic review and meta-analysis. Front Cardiovasc Med. 2023;10:1131251. doi: 10.3389/fcvm.2023.1131251.
   PubMed Web of Science ®Google Scholar
• Zhu D, Chung HF, Dobson AJ, et al. Type of menopause, age of menopause and variations in the risk of incident cardiovascular disease: pooled analysis of individual data from 10 international studies. Hum Reprod. 2020;35(8):1933–1943. doi: 10.1093/humrep/deaa124.
   PubMed Web of Science ®Google Scholar
• Price MA, Alvarado BF, Rosendaal NTA, et al. Early and surgical menopause associated with higher Framingham Risk Scores for cardiovascular disease in the Canadian Longitudinal Study on Aging. Menopause. 2021;28(5):484–490. doi: 10.1097/GME.0000000000001729.
   PubMed Web of Science ®Google Scholar
• Gunning MN, Meun C, van Rijn BB, et al. The cardiovascular risk profile of Middle age women previously diagnosed with premature ovarian insufficiency: a case-control study. PLoS One. 2020;15(3):e0229576. doi: 10.1371/journal.pone.0229576.
   PubMed Web of Science ®Google Scholar
• Ardissino M, Slob EAW, Carter P, et al. Sex-specific reproductive factors augment cardiovascular disease risk in women: a Mendelian randomization study. J Am Heart Assoc. 2023;12(5):e027933. doi: 10.1161/JAHA.122.027933.
   PubMed Web of Science ®Google Scholar
• Cho L, Davis M, Elgendy I, et al. Summary of updated recommendations for primary prevention of cardiovascular disease in women: JACC State-of-the-Art review. J Am Coll Cardiol. 2020;75(20):2602–2618. doi: 10.1016/j.jacc.2020.03.060.
   PubMed Web of Science ®Google Scholar
• Ivey SL, Hanley HR, Taylor C, et al. Early identification and treatment of women’s cardiovascular risk factors prevents cardiovascular disease, saves lives, and protects future generations: policy recommendations and take action plan utilizing policy levers. Clin Cardiol. 2022;45(11):1100–1106. doi: 10.1002/clc.23921.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life’s essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health: a presidential advisory from the American Heart Association. Circulation. 2022;146(5):e18–e43. doi: 10.1161/CIR.0000000000001078.
   PubMed Web of Science ®Google Scholar
• Mehta LS, Velarde GP, Lewey J, et al. Cardiovascular disease risk factors in women: the impact of race and ethnicity: a scientific statement from the American Heart Association. Circulation. 2023;147(19):1471–1487. doi: 10.1161/CIR.0000000000001139.
   PubMed Web of Science ®Google Scholar